Aarti Drugs Limited (AARTIDRUGS) - Total Liabilities
Based on the latest financial reports, Aarti Drugs Limited (AARTIDRUGS) has total liabilities worth Rs11.44 Billion INR (≈ $123.68 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore AARTIDRUGS shareholders equity momentum to track the company's year-over-year net asset growth rate.
Aarti Drugs Limited - Total Liabilities Trend (2006–2025)
This chart illustrates how Aarti Drugs Limited's total liabilities have evolved over time, based on quarterly financial data. See Aarti Drugs Limited free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Aarti Drugs Limited Competitors by Total Liabilities
The table below lists competitors of Aarti Drugs Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nawi Brothers Group Ltd
TA:NAWI
|
Israel | ILA3.88 Billion |
|
Shanghai Ailu Package Co. Ltd.
SHE:301062
|
China | CN¥1.42 Billion |
|
Bank7 Corp
NASDAQ:BSVN
|
USA | $1.69 Billion |
|
VST Industries Limited
NSE:VSTIND
|
India | Rs5.70 Billion |
|
EGing Photovoltaic Technology Co Ltd
SHG:600537
|
China | CN¥4.12 Billion |
|
Kuo Toong International Co Ltd
TWO:8936
|
Taiwan | NT$5.52 Billion |
|
Ophir High Conviction Fund
AU:OPH
|
Australia | AU$28.68 Million |
|
CIMB Thai Bank Public Company Limited
BK:CIMBT
|
Thailand | ฿498.85 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Aarti Drugs Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AARTIDRUGS market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.01 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aarti Drugs Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aarti Drugs Limited (2006–2025)
The table below shows the annual total liabilities of Aarti Drugs Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs12.05 Billion ≈ $130.35 Million |
+4.78% |
| 2024-03-31 | Rs11.50 Billion ≈ $124.41 Million |
-6.38% |
| 2023-03-31 | Rs12.29 Billion ≈ $132.88 Million |
+4.87% |
| 2022-03-31 | Rs11.72 Billion ≈ $126.71 Million |
+37.42% |
| 2021-03-31 | Rs8.53 Billion ≈ $92.21 Million |
-7.73% |
| 2020-03-31 | Rs9.24 Billion ≈ $99.93 Million |
+0.50% |
| 2019-03-31 | Rs9.19 Billion ≈ $99.43 Million |
-1.40% |
| 2018-03-31 | Rs9.33 Billion ≈ $100.85 Million |
+21.63% |
| 2017-03-31 | Rs7.67 Billion ≈ $82.91 Million |
+2.94% |
| 2016-03-31 | Rs7.45 Billion ≈ $80.55 Million |
+7.35% |
| 2015-03-31 | Rs6.94 Billion ≈ $75.03 Million |
+15.86% |
| 2014-03-31 | Rs5.99 Billion ≈ $64.76 Million |
+16.94% |
| 2013-03-31 | Rs5.12 Billion ≈ $55.38 Million |
+17.42% |
| 2012-03-31 | Rs4.36 Billion ≈ $47.17 Million |
+21.05% |
| 2011-03-31 | Rs3.60 Billion ≈ $38.97 Million |
+32.16% |
| 2010-03-31 | Rs2.73 Billion ≈ $29.48 Million |
-2.56% |
| 2009-03-31 | Rs2.80 Billion ≈ $30.26 Million |
-8.30% |
| 2008-03-31 | Rs3.05 Billion ≈ $33.00 Million |
+14.61% |
| 2007-03-31 | Rs2.66 Billion ≈ $28.79 Million |
-0.11% |
| 2006-03-31 | Rs2.66 Billion ≈ $28.82 Million |
-- |
About Aarti Drugs Limited
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enro… Read more